Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
| Autor: | TA Mansfield, Agata Ptaszynska, Shamik Parikh, Eva Johnsson, Yshai Yavin, Kristina Johnsson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
endocrine system diseases
Hyperkalemia Endocrinology Diabetes and Metabolism Potassium chemistry.chemical_element Hypokalemia 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Pharmacology urologic and male genital diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus Type 2 diabetes mellitus Internal Medicine Medicine Dapagliflozin Sodium glucose co-transporter 2 inhibitor Original Research business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus medicine.disease Clinical trial chemistry medicine.symptom SGLT2 Inhibitor business |
| Zdroj: | Diabetes Therapy |
| ISSN: | 1869-6961 1869-6953 |
| DOI: | 10.1007/s13300-015-0150-y |
| Popis: | Introduction Hyperkalemia risk is increased in diabetes, particularly in patients with renal impairment or those receiving angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or potassium-sparing diuretics. Conversely, other diuretics can increase hypokalemia risk. We assessed the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on serum potassium levels in a pooled analysis of clinical trials in patients with type 2 diabetes mellitus (T2DM). Methods Fourteen randomized, placebo-controlled, double-blind T2DM studies were analyzed: pooled data from 13 studies of ≤24 weeks’ duration (dapagliflozin 10 mg, N = 2360; placebo, N = 2295); and one 52-week moderate renal impairment study in patients with baseline eGFR ≥30 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|